Pages that link to "Q28343012"

The following pages link to Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission (Q28343012):

Displaying 20 items.

• Corticostriatal Dysfunction in Huntington's Disease: The Basics (Q26738379) (← links)
• Dopamine Receptors and Neurodegeneration (Q26783348) (← links)
• Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases (Q26830654) (← links)
• Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity (Q33831774) (← links)
• Neuronal cell death in Huntington's disease: a potential role for dopamine (Q33934225) (← links)
• Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. (Q36300365) (← links)
• Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. (Q37930190) (← links)
• Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility (Q38121068) (← links)
• The role of dopamine in Huntington's disease (Q38223504) (← links)
• Dopamine and Huntington's disease. (Q38379277) (← links)
• Cerebrospinal Fluid Biomarkers for Huntington's Disease (Q38794551) (← links)
• Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation (Q39041217) (← links)
• Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. (Q43662825) (← links)
• Serum iron, total iron binding capacity and ferritin in early Huntington disease patients (Q45289544) (← links)
• Disease-modifying effects of ganglioside GM1 in Huntington's disease models. (Q47154575) (← links)
• Disrupted striatal neuron inputs and outputs in Huntington's disease. (Q52690256) (← links)
• A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward. (Q52721984) (← links)
• Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review (Q64968129) (← links)
• Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice (Q99638675) (← links)
• Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot study (Q102379328) (← links)